Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Date of Filing: June 26, 2026
Principal Executive Offices: Ramat Gan, Israel
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
On June 26, 2026, the company announced the securing of a Japanese patent allowance for Namodenoson's anti-obesity technology. This represents a significant regulatory and intellectual property milestone for the company's lead asset.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the first three paragraphs of a press release regarding the Japanese patent allowance by reference into the company's Registration Statements on Form S-8 and Form F-3.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard incorporation of the press release.
Investor Verification Checklist
- Verify the scope and validity of the Japanese patent allowance for Namodenoson's anti-obesity technology.
- Review the full text of the press release (Exhibit 99.1) for details on the patent's impact on commercialization timelines in Japan.
- Confirm the status of Namodenoson's regulatory filings in other key markets.